Hyperlipidemia Medications: From Statins to Gene Editing

Hyperlipidemia medications span more than a dozen drug classes, each lowering harmful blood lipids through a different biological route. Statins remain the cornerstone for most people, but the landscape has expanded dramatically over the past decade with injectable antibodies, RNA-silencing drugs, and even early-stage gene-editing approaches. Which medication your doctor reaches for depends on the specific lipid problem, how well you tolerate the first-line option, and how aggressively your cholesterol needs to come down.

Statins and Why They Still Come First

Statins work by blocking an enzyme in the liver called HMG-CoA reductase, which is central to the body’s own cholesterol-manufacturing process. When this enzyme is inhibited, the liver compensates by pulling more LDL cholesterol out of the bloodstream, and circulating levels drop.¹ That straightforward mechanism explains most of the benefit, but it is not the whole story. Statins also appear to improve how blood vessel walls function, reduce inflammation inside arteries, and make existing plaques less likely to rupture and trigger a heart attack.² Part of that vascular benefit comes from increased production of nitric oxide, a molecule that helps blood vessels relax and stay flexible.³ These extra effects help explain why statins reduce heart attacks and strokes by a larger margin than you would predict from cholesterol lowering alone.

Seven statins are available, ranging from lower-potency options like pravastatin to high-potency agents like atorvastatin and rosuvastatin. The choice often depends on how far your LDL needs to fall, other medications you take, and your tolerance for side effects. One practical quirk of statin dosing: doubling the dose only lowers LDL by another 5 to 6 percent on average, which is why physicians often add a second drug rather than keep pushing the statin higher.⁴

Muscle Symptoms and the Nocebo Question

Muscle complaints are the most common reason people stop taking statins. Self-reported muscle pain among statin users can appear very high in surveys, but the reported rate varies wildly depending on how the question is asked and whether the study includes a placebo comparison. The National Lipid Association estimates that about one in ten statin users experiences some muscle symptom, though the range in practice sits between roughly 5 and 25 percent.⁵ However, when researchers compare the share of symptoms actually caused by the drug’s chemistry, the figure shrinks to about 1 to 2 percent.⁶ The mechanisms behind genuine statin muscle injury are not fully understood, but proposed contributors include disrupted energy production inside muscle cells and genetic susceptibility.⁷

The gap between how many people feel muscle pain on a statin and how many are experiencing a true pharmacological side effect points to the nocebo effect, where expecting a side effect makes it more likely you will notice one. In focus groups, patients who had stopped statins acknowledged that the nocebo effect exists in principle but were unanimous in believing it did not apply to them personally, citing the severity of their symptoms and the relief they felt after stopping the drug.⁸ That psychological reality matters, because muscle symptoms are clinically relevant regardless of cause. A medication that people stop taking does not prevent heart attacks, and statin discontinuation carries real cardiovascular consequences.⁹ For people who truly cannot tolerate statins, the good news is that several non-statin options now exist.

Ezetimibe and Why Combination Therapy Works

Ezetimibe blocks cholesterol absorption in the small intestine by targeting a transport protein on the surface of intestinal cells.¹⁰ Because it works through a completely different pathway than statins, the two drugs combined lower LDL more effectively than either alone. A large trial comparing moderate-intensity statin plus ezetimibe against high-intensity statin alone found that the combination group was significantly more likely to reach an LDL target below 70 mg/dL at every yearly check, with roughly three-quarters of patients hitting that goal compared to about 55 to 60 percent on high-dose statin monotherapy.¹¹ That approach also means less statin-related muscle risk, since the statin dose can stay lower. Ezetimibe is generally very well tolerated and is available as a generic, making it one of the easiest add-on choices.

PCSK9 Inhibitors

PCSK9 is a protein the liver makes that chews up LDL receptors on liver cells. Fewer receptors means less LDL gets cleared from the blood. Blocking PCSK9 preserves those receptors, and LDL levels plummet. Two monoclonal antibodies, evolocumab and alirocumab, are injected every two to four weeks and can lower LDL by roughly 44 to 65 percent on top of statin therapy.¹² They also reduce apolipoprotein B and lipoprotein(a), another atherogenic particle.¹³ Clinical trials confirmed the expected reduction in cardiovascular events, which pushed PCSK9 inhibitors into guidelines for people at very high risk who cannot reach their LDL target with statins and ezetimibe alone.

The newer entrant in this space is inclisiran, a small interfering RNA that silences the gene encoding PCSK9 in the liver. Instead of blocking the protein after it is made, inclisiran stops the liver from producing PCSK9 in the first place. The practical advantage is dosing: after two initial loading injections, inclisiran is given just twice a year and lowers LDL by about 50 percent versus placebo when added to maximally tolerated statin therapy.¹⁴ A sugar molecule attached to the drug directs it straight to liver cells, where its effects on PCSK9 suppression and LDL reduction last more than six months despite the drug itself being undetectable in blood within about 48 hours.¹⁵ For people who struggle with frequent injections or daily pills, twice-yearly dosing at a doctor’s office removes the adherence problem entirely.

Bempedoic Acid

Bempedoic acid targets a step in cholesterol production that sits upstream of the step statins block, inhibiting an enzyme called ATP citrate lyase in the liver.¹⁶ The net result is similar: liver cholesterol drops, LDL receptors get upregulated, and more LDL is pulled from the bloodstream. What makes bempedoic acid especially attractive for statin-intolerant patients is that it is a prodrug activated only inside liver and kidney cells. It is not activated in skeletal muscle, so the muscle toxicity associated with statins is largely absent.¹⁷ It is taken as a daily pill and is available in a fixed-dose combination tablet with ezetimibe, giving two non-statin mechanisms in a single pill.

Fibrates for High Triglycerides

Not every lipid problem is about LDL. Some people have dangerously elevated triglycerides, sometimes high enough to trigger pancreatitis. Fibrates (gemfibrozil, fenofibrate, bezafibrate) activate a nuclear receptor called PPAR-alpha, which flips on genes involved in breaking down fats.¹⁸ The downstream effect is a two-pronged drop in triglycerides: the liver produces less triglyceride-rich VLDL particles, and the body clears the ones already circulating faster through enhanced breakdown.¹⁹ Fibrates also raise HDL cholesterol by boosting production of the proteins that form HDL particles. Their role in cardiovascular risk reduction is less clear-cut than statins’, and they are typically reserved for severe triglyceride elevations or used alongside statins when triglycerides remain stubbornly high after LDL has been addressed.

Prescription Omega-3 Fatty Acids

Fish oil supplements line every pharmacy shelf, but prescription omega-3 products are a different category entirely. The distinction that matters most: icosapent ethyl, a purified form of the omega-3 fatty acid EPA, significantly reduced cardiovascular events by about 25 percent in a landmark trial of patients with elevated triglycerides who were already on statins.²⁰ Mixed omega-3 products that combine EPA with DHA did not show the same benefit. Trials testing those combinations found that adding DHA appeared to eliminate the protective effect of EPA alone.²¹ And over-the-counter fish oil supplements are regulated as dietary supplements, not drugs, meaning their potency and purity are not held to pharmaceutical standards.²² The upshot: store-bought fish oil and prescription icosapent ethyl are not interchangeable, despite sounding similar.

Bile Acid Sequestrants

Bile acid sequestrants, such as cholestyramine, colestipol, and colesevelam, are among the oldest lipid-lowering drugs. They work in the gut, binding bile acids and preventing their reabsorption. The liver, needing bile acids to digest fats, responds by converting more of its cholesterol into new bile acids, which lowers hepatic cholesterol stores and triggers the liver to pull more LDL out of the blood.²³ Colesevelam has an interesting secondary benefit: it modestly improves blood sugar control in people with type 2 diabetes, in part by increasing gut hormones like GLP-1.²⁴ Bile acid sequestrants are not first-line for most adults because they lower LDL less dramatically than statins and can cause bloating and constipation, but they remain useful in patients who cannot take other medications or who need help with both cholesterol and glucose.

Where Niacin Stands Now

Niacin (vitamin B3) is the most potent drug for raising HDL cholesterol and was once a go-to therapy. Its fall from favor was swift. Two large randomized trials comparing niacin to placebo in patients already receiving statin therapy found no reduction in heart attacks, strokes, or death.²⁵ When a systematic review pulled together the broader evidence, the conclusion was the same: niacin did not significantly reduce cardiovascular events or mortality in people with or at risk for heart disease.²⁶ Add in the side effects, particularly intense skin flushing, liver toxicity, and worsened blood sugar, and most guidelines now relegate niacin to a rarely used option. Raising HDL turned out not to translate into fewer heart attacks the way lowering LDL does.

Drugs for Severe Genetic Cholesterol Disorders

Some people inherit mutations that make their LDL receptors partly or completely nonfunctional. Homozygous familial hypercholesterolemia, the most severe form, can push LDL levels above 500 mg/dL in childhood and cause heart attacks before age 20. Statins rely on working LDL receptors to pull cholesterol from the blood, so they are far less effective in these patients. Several drugs have been developed specifically for this population.

Evinacumab is a monoclonal antibody that blocks a protein called ANGPTL3, lowering LDL through a pathway that does not depend on LDL receptors at all.²⁷ In a trial of patients with homozygous familial hypercholesterolemia, evinacumab reduced LDL by about 47 percent compared to baseline, while LDL in the placebo group barely budged.²⁸ A case report of a teenager on evinacumab illustrated the real-world impact: his time-averaged LDL dropped by more than half, and the family was able to reduce the frequency of LDL apheresis sessions, a burdensome blood-filtering procedure, from every two weeks to monthly.²⁹

Two other drugs occupy this niche. Lomitapide, a daily capsule, blocks the protein that assembles triglyceride-rich lipoproteins in the liver, while mipomersen, an injected antisense therapy, targets the messenger RNA for apolipoprotein B-100, the structural protein of LDL particles, preventing it from being made.³⁰ Both carry significant liver-related side effects and are restricted to patients with confirmed homozygous familial hypercholesterolemia under close monitoring.

Targeting Lipoprotein(a)

Lipoprotein(a), or Lp(a), is a genetically determined particle that roughly one in five people carries at elevated levels. High Lp(a) raises the risk of heart disease and calcific aortic valve disease, and none of the standard lipid drugs bring it down meaningfully.³¹ That gap has made Lp(a) one of the hottest targets in cardiovascular drug development.

Pelacarsen is an antisense oligonucleotide in phase 3 testing that blocks the liver from making the apolipoprotein(a) component of Lp(a).³² A large outcomes trial is underway to determine whether lowering Lp(a) with pelacarsen actually prevents heart attacks and strokes.³³ Other approaches, including small interfering RNAs and gene editing aimed at the same target, are also in development. Until the outcomes data arrive, high Lp(a) remains a risk factor you can measure but cannot do much about pharmacologically. If the trials succeed, Lp(a)-lowering drugs would represent the first entirely new class of proven cardiovascular therapy in years.

Cost and Access

The explosion of new lipid drugs has come with sticker shock. Generic statins cost pennies per day, and generic ezetimibe is similarly affordable. PCSK9 monoclonal antibodies, by contrast, remain expensive. A meta-analysis of cost-utility studies found that PCSK9 inhibitors were not cost-effective compared to standard lipid-lowering therapy across multiple economic analyses, regardless of whether the comparator was statin therapy, placebo, or no treatment.³⁴ A separate modeling study found that icosapent ethyl had a 100 percent probability of being cost-effective for secondary prevention at a common willingness-to-pay threshold, while PCSK9 inhibitors had essentially a zero percent probability at that same threshold.³⁵ Manufacturers have reduced list prices in some markets, and insurer coverage has expanded for very high-risk patients, but access remains uneven. For many people, the most effective strategy from both a clinical and cost perspective is still a generic statin combined with generic ezetimibe.

Kidney Disease and Lipid Therapy

People with chronic kidney disease face elevated cardiovascular risk, and managing their lipids involves some specific considerations. European guidelines recommend aggressive LDL targets for patients with advanced kidney disease, below 55 mg/dL for those with severely reduced kidney function.³⁶ The largest trial in this population tested simvastatin combined with ezetimibe in over 9,000 patients with stage 3 through 5 kidney disease and found a 17 percent reduction in a composite of major cardiovascular events.³⁷ The benefit appeared primarily in those not yet on dialysis. For dialysis patients, the evidence for starting lipid-lowering therapy is weaker, and guidelines are more cautious. Drug choice also matters, since some statins are cleared through the kidneys and need dose adjustments in renal impairment, while others are cleared primarily by the liver and require less modification.

Beyond LDL as the Sole Target

Most treatment decisions revolve around LDL cholesterol, but there has been growing interest in apolipoprotein B, the protein embedded in every LDL, VLDL, and Lp(a) particle. Because each atherogenic particle carries exactly one apoB molecule, measuring apoB gives a direct count of all the particles that can burrow into artery walls, not just the cholesterol riding inside them. Data suggest that apoB outperforms LDL cholesterol in predicting cardiovascular risk, yet it has not been widely adopted into routine practice.³⁸ This matters for medication decisions because two people with the same LDL number can have very different apoB levels, and therefore different amounts of actual risk. One person’s LDL may be carried in a few large, cholesterol-rich particles, while another’s is spread across many small, dense particles. The person with more particles (higher apoB) may need more aggressive treatment even though their standard lab report looks similar.

Gene Editing on the Horizon

The most futuristic entries in the lipid-lowering pipeline involve permanently editing genes in the liver. A phase 1 trial has tested CTX310, a CRISPR-Cas9 therapy delivered intravenously that introduces a loss-of-function mutation into the ANGPTL3 gene in liver cells.³⁹ The appeal is obvious: a single infusion could theoretically provide lifelong cholesterol lowering without any ongoing medication. Similar strategies are being explored for PCSK9, where editing the gene out of commission would mimic the natural protection seen in people born with loss-of-function PCSK9 mutations, who have very low LDL and very low rates of heart disease.⁴⁰ These approaches are years from routine clinical use, and questions about long-term safety, off-target edits, and whether durability truly lasts a lifetime remain open. But for patients with severe genetic cholesterol disorders who currently face lifelong injections or blood-filtering procedures, the promise of a one-time treatment is more than speculative. It is actively being tested in humans.